Business
Volition Continues to Extend Access to Nu.Q® Vet Cancer Test
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized laboratory providers of its Nu.Q® Vet Cancer test in the U.S. and Asia, further expanding access to its canine cancer early detection tool.
About this update from Volitionrx Limited
[{"type":"text","content":"HENDERSON, Nev., Jan. 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized laboratory providers of its Nu.Q® Vet Cancer test in the U.S. and Asia, further expanding access to its canine cancer early detection tool.","length":343,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Midwest Veterinary Laboratory, a full-service independent reference laboratory in the U.S., will be offering the Nu.Q® Vet Cancer test to its customers across all 50 states from February 2026.","length":192,"tagName":"p"}]},{"val":[{"type":"text","content":"Bioguard, a global animal health diagnostics company is now offering the Nu.Q® Vet Cancer Test through it's Animal Health Diagnostic Center, the first certified ISO/IEC 17025 animal disease testing laboratory in Taiwan and China.","length":233,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":425,"olType":false},{"type":"text","content":"Dr. Tom Butera, Chief Executive Officer, Volition Veterinary Diagnostics Development LLC commented:","length":99,"tagName":"p"},{"type":"text","content":""We are delighted to extend the availability of our groundbreaking Nu.Q® technology in both the U.S. and Asia through these well established reference labs.","length":161,"tagName":"p"},{"type":"text","content":"By incorporating the Nu.Q® Canine Cancer Test into annual checkups or regular senior wellness exams, veterinarians can detect cancer earlier[1] and help pet owners make timely, informed decisions about cancer care.","length":219,"tagName":"p"},{"type":"text","content":""The market opportunity for Nu.Q® Vet is considerable, with the Total Addressable Market for Canine Screening approximately $100 million for the U.S., Europe and Japan and would increase to a little under $150 million with the addition of China[2]."","length":259,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Wilson-Robles, H.M., Bygott, T., Kelly, T.K. et al. Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs. BMC Vet Res 18, 329 (2022). https://doi.org/10.1186/s12917-022-03429-8","length":231,"tagName":"p"}]},{"val":[{"type":"text","content":"Data on File: Volition TAM","length...